ABSTRACT
Atherosclerotic Cardiovascular Disease (ASCVD) represents the leading cause of death worldwide, and individual screening should be based on behavioral, metabolic, and genetic profile derived from data collected in large population-based studies. Due to a polygenic nature of ASCVD, we aimed to assess the association of genomics to ASCVD risk and its impact on the occurrence of acute myocardial infarction, stroke, or peripheral artery thrombotic-ischemic events on a population level. CV-GENES is a multicenter, Brazilian nationwide, 1:1 case-control study of 3,734 patients. Inclusion criteria for cases are the first occurrence of one of the cardiovascular events. Individuals without known ASCVD, and age- and sex-matched will be eligible for the control group. A genetics core lab analysis will be performed through the association of low-pass whole genome sequencing and whole exome sequencing. A polygenic risk score will be built in a multiethnic population to estimate the association between genetic polymorphisms and risk of ASCVD. In addition, the presence of pathogenic or likely pathogenic variants will be screened in 8 genes (ABCG5, ABCG8, APOB, APOE, LDLR, LDLRAP1, LIPA, PCSK9) associated with atherosclerosis. Multiple logistic regression will be applied to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs), and population attributable risks will be calculated. This study is registered in clinicaltrials.gov (NCT05515653.)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study is registered in clinicaltrials.gov (NCT05515653).
Clinical Protocols
https://clinicaltrials.gov/study/NCT05515653?term=NCT05515653&rank=1
Funding Statement
This study was funded by the Institutional Development Program – Brazilian Unified Health System (PROADI-SUS), Brazilian Ministry of Health. The funder has no role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Hospital Alemão Oswaldo Cruz received and administrated the fund. None of the authors received direct fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been approved by the Institutional Review Board (IRB) at Hospital Alemão Oswaldo Cruz and by all local Ethics Committees at each participating site (CAAE - 56482922.2.1001.0070), on April 22nd, 2022. Any changes will be treated as protocol amendments and will be immediately submitted to IRB. All patients need to sign two informed consent forms (general study and biobank), which will be applied to both cases and controls in each research center by delegated researchers and physicians. A specific anonymized id will be assigned to each participant and their biological samples. Data will be stored in a secure and encrypted cloud, and all patient data will be totally anonymized. This study is registered in clinicaltrials.gov (NCT05515653) and is currently recruiting. First patient was recruited in July 2022. The estimated completion date is April 2024
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as clinicaltrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion
